Abstract
Ghrelin is a gastric hormone that stimulates growth hormone (GH) secretion and food intake to regulate energy homeostasis and body weight by binding to its receptor, GH secretagogue receptor (GHSR1a), which is most highly expressed in the pituitary and hypothalamus. Nowadays there is considerable evidence showing that the GHSR1a is also expressed in numerous extra-hypothalamic neuronal populations and the physiological role of ghrelin is by far wider than considered before including learning and memory, anxiety, depression and neuroprotection. The present review attempts to provide a comprehensive picture of the role of ghrelin in the central nervous system and to highlight recent findings showing its potential as an innovative therapeutic agent in neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.
Keywords: Ghrelin, neuroprotection, Alzheimer’s disease, Parkinson’s disease, learning and memory, anxiety, depression
Current Pharmaceutical Design
Title:Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Volume: 19 Issue: 38
Author(s): Vanessa V. dos Santos, Ana Lúcia S. Rodrigues, Thereza C. De Lima, Susana R. de Barioglio, Rita Raisman-Vozari and Rui D. Prediger
Affiliation:
Keywords: Ghrelin, neuroprotection, Alzheimer’s disease, Parkinson’s disease, learning and memory, anxiety, depression
Abstract: Ghrelin is a gastric hormone that stimulates growth hormone (GH) secretion and food intake to regulate energy homeostasis and body weight by binding to its receptor, GH secretagogue receptor (GHSR1a), which is most highly expressed in the pituitary and hypothalamus. Nowadays there is considerable evidence showing that the GHSR1a is also expressed in numerous extra-hypothalamic neuronal populations and the physiological role of ghrelin is by far wider than considered before including learning and memory, anxiety, depression and neuroprotection. The present review attempts to provide a comprehensive picture of the role of ghrelin in the central nervous system and to highlight recent findings showing its potential as an innovative therapeutic agent in neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.
Export Options
About this article
Cite this article as:
V. dos Santos Vanessa, S. Rodrigues Ana Lúcia, C. De Lima Thereza, R. de Barioglio Susana, Raisman-Vozari Rita and D. Prediger Rui, Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/13816128113199990411
DOI https://dx.doi.org/10.2174/13816128113199990411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ca2+ Fluxes Involvement in Gene Expression During Cardiac Hypertrophy
Current Vascular Pharmacology Fatty Acids and Obesity
Current Pharmaceutical Design Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Visceral Adipose Tissue and Atherosclerosis
Current Vascular Pharmacology FXR, A Therapeutic Target for Bile Acid and Lipid Disorders
Mini-Reviews in Medicinal Chemistry Kinetic Measurement Techniques in the Evaluation of Lipid Metabolism
Current Drug Discovery Technologies Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Chemokines and Atherosclerotic Plaque Progression: Towards Therapeutic Targeting?
Current Pharmaceutical Design Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice
Current Pharmaceutical Biotechnology Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Reviews on Recent Clinical Trials Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews Antithrombotic Treatment in the Prevention of Ischemic Stroke
Current Drug Targets Meet Our Editorial Board Member
Current Cardiology Reviews The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Adenosine and Adenosine Receptors in the Pathomechanism and Treatment of Respiratory Diseases
Current Medicinal Chemistry Synthetic Thioamide, Benzimidazole, Quinolone and Derivatives with Carboxylic Acid and Ester Moieties: A Strategy in the Design of Antituberculosis Agents
Current Medicinal Chemistry Editorial (Thematic Issues: Autoimmunity and Autoinflammation: Cardiovascular Drug Targets and Design)
Current Pharmaceutical Design